Compare GE Aerospace (GE) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Medpace Holdings Inc — how do they compare? GE Aerospace trades at $366.04 (market cap $379.05B), while Medpace Holdings Inc trades at $601 (market cap $16.66B). The key difference: GE Aerospace is far larger — about 22.8× Medpace Holdings Inc's market cap, and GE Aerospace pays a 0.51% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GE | MEDP | |
|---|---|---|
Market Cap | $379.05B | $16.66B |
Sector | Industrials | Technology |
52-Week High | $381.22 | $620.59 |
52-Week Low | $265.93 | $393.42 |
Enterprise Value | $388.86B | $16.28B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $368.06, up 0.37% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.02 beating expectations and revenue growth accelerating to $45.86B in 2025. Recent defense contract wins and commercial engine demand fuel optimism, though elevated valuation metrics warrant caution.
Outlook remains positive with 68.6% analyst buy ratings and $414.11 consensus target suggesting 12.5% upside. Key risks include high debt levels and rich valuations, but strong order backlog and defense contracts provide growth catalysts. Earnings momentum and institutional support position GE for continued outperformance in aerospace sector.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
